Afeletecan

Drug Profile

Afeletecan

Alternative Names: BAY 38-3441

Latest Information Update: 22 Mar 2010

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Bayer
  • Class Antineoplastics; Camptothecins; Dipeptides; Glycoconjugates
  • Mechanism of Action DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Breast cancer; Cancer; Colorectal cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Small cell lung cancer

Most Recent Events

  • 26 Nov 2002 Results from two phase I studies have been added to the adverse events and Cancer therapeutic trials sections
  • 25 Nov 2002 A study has been added to the adverse events, pharmacokinetics and Cancer therapeutic trials sections
  • 10 Dec 2001 A phase I study has been added to the Cancer pharmacokinetics and adverse events section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top